A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicinal products.

ABSTRACT:

Background

Hormonal replacement therapy is widely used to treat conditions in humans, the most well-known indication being the relief of menopausal symptoms in women. Many of the hormone-containing products (HCP) are applied to the skin. This transdermal delivery poses a risk to animals and humans through secondary exposure, especially when product information is not strictly followed. The aim of this article is to raise awareness among veterinarians and human healthcare providers of this risk; based on evidence from spontaneous reporting of suspected adverse events (AEs) in animals and humans. Interventions are also explored to mitigate the risk of secondary exposure to transdermal HCP (THCP).

Review of spontaneously reported suspected aes

The Swedish Medical Products Agenc

SUBMITTER: Sjostrom K 

PROVIDER: S-EPMC9614385 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature